Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Generic Pharmaceutical Market: By Brand, By Route of Drug Administration, By Application, Cardiovascular Disease, Infectious Disease, Musculoskeletal Disease, Dermatology, Oncology, Respiratory, and Others), By Distribution Channel and Geography
Generic Pharmaceutical Market size was valued at US$ 459.68 billion in 2023 and is poised to grow at a significant CAGR of 5.5% over 2024-2030. A generic drug has exactly the same active ingredient as the brand-name drug and shows the same therapeutic effect. It is the same in dosing, safety, strength, method of administration, and quality. According to the U.S. Food and Drug Administration (FDA), a generic drug can only be marketed after the brand-name drug's patent has expired, which may take up to 20 years after the patent holder's drug is on the market. Generic drugs are usually less expensive than brand-name drugs. The crucial factors accountable for market growth are the low cost of generic drugs, and a large number of branded drug patents are going to expire. Also, the increasing use of robotic process automation (RPA), AI technology, Insilco method for drug discovery is providing lucrative growth prospects to the generic pharmaceutical market.
However, the prevalence of chronic diseases like cardiovascular disorders (heart attacks and strokes), malignancies, and chronic respiratory diseases like asthma, and diabetes are also driving the market. These diseases impact people of all ages around the world due to the rapid growth of unplanned urbanization, the globalization of unhealthy lifestyles, and population aging. For instance, according to IDF, approximately 537 million adults (20-79 years) are living with diabetes. The total number of people who have diabetes is projected to rise to 643 million by 2030 and 783 million by 2045. In spite of the growth of the generic pharmaceutical market, the FDA's stringent approval and distribution, high competition, and shortage of drugs are hindering the growth of the generic pharmaceutical market.
Study Period
2024-2030Base Year
2023CAGR
5.5%Largest Market
North AmericaFastest Growing Market
North America
Chronic diseases are long-term illnesses that last for 3 months or longer like heart attacks, strokes, malignancies, and chronic respiratory diseases such as asthma, and diabetes. For instance, an estimated 17.9 million people died from cardiovascular diseases in 2019, representing 32% of all global deaths of which 85% were due to heart attack and stroke. Moreover, 75% of incidents occurred in underdeveloped countries due to poor nutrition, lack of physical exercise, tobacco smoke exposure, and alcohol consumption. According to WHO, 22.3% of the global population used tobacco, 36.7% of all men, and 7.8% of the world's women in 2021. The chances of occurring chronic disease are increasing due to rapid urbanization, and unhealthy lifestyles which fueled the growth of the generic pharmaceutical market.
Report Benchmarks |
Details |
Report Study Period |
2024-2030 |
Market Size in 2023 |
US$ 459.68 billion |
Market CAGR |
5.5% |
By Brand |
|
By Route Administration |
|
By Distribution Channel |
|
Download Free Sample Report
The generic pharmaceutical market size was valued at US$ 459.68 billion in 2023
Abbott Laboratories, Amgen, Apotex, Mylan, Pfizer, ASKA Pharmaceutical
North America is the fastest-growing region for generic pharmaceutical market
1. Executive Summary |
2. Global Generic Pharmaceutical Market Introduction |
2.1. Global Generic Pharmaceutical Market Taxonomy |
2.2. Global Generic Pharmaceutical Market Definitions |
2.2.1. By Brand |
2.2.2. By Route of Drug Administration |
2.2.3. By Application |
2.2.4. By Distribution channel |
2.2.5. By Region |
3. Global Generic Pharmaceutical Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Global Generic Pharmaceutical Market Dynamic Factors - Impact Analysis |
3.6. Global Generic Pharmaceutical Market Competition Landscape |
3.7. Epidemiology |
4. Global Generic Pharmaceutical Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 |
4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5. Global Generic Pharmaceutical Market, By Brand, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
5.1. Pure Generic Drugs |
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Branded Generic Drugs |
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
6. Global Generic Pharmaceutical Market, By Route of Drug Administration, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
6.1. Oral |
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Topical |
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Parental |
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
6.4. Others |
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.4.3. Market Opportunity Analysis |
7. Global Generic Pharmaceutical Market, By Application, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
7.1. Central Nervous System (CNS) |
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Cardiovascular Disease (CVDs) |
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Infectious Disease |
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
7.4. Musculoskeletal Disease |
7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.4.3. Market Opportunity Analysis |
7.5. Dermatology |
7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.5.3. Market Opportunity Analysis |
7.6. Oncology |
7.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
7.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.6.3. Market Opportunity Analysis |
7.7. Respiratory |
7.7.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
7.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.7.3. Market Opportunity Analysis |
7.8. Others |
7.8.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
7.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.8.3. Market Opportunity Analysis |
8. Global Generic Pharmaceutical Market, By Distribution channel, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
8.1. Hospitals Pharmacies |
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Retail Pharmacies |
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Others |
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
9. Global Generic Pharmaceutical Market Forecast, By Region, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
9.1. North America |
9.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.1.3. Market Opportunity Analysis |
9.2. Europe |
9.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.2.3. Market Opportunity Analysis |
9.3. Asia-Pacific |
9.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.3.3. Market Opportunity Analysis |
9.4. Latin America |
9.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.4.3. Market Opportunity Analysis |
9.5. Middle East and Africa |
9.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.5.3. Market Opportunity Analysis |
9.6. Global Generic Pharmaceutical Market - Opportunity Analysis Index, By Brand, By Route of Drug Administration, By Application, By Distribution channel, and Region, 2024 - 2030 |
10. North America Generic Pharmaceutical Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
10.1. Brand Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
10.1.1. Pure Generic Drugs |
10.1.2. Branded Generic Drugs |
10.2. Route of Drug Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
10.2.1. Oral |
10.2.2. Topical |
10.2.3. Parental |
10.2.4. Others |
10.3. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
10.3.1. Central Nervous System (CNS) |
10.3.2. Cardiovascular Disease (CVDs) |
10.3.3. Infectious Disease |
10.3.4. Musculoskeletal Disease |
10.3.5. Dermatology |
10.3.6. Oncology |
10.3.7. Respiratory |
10.3.8. Others |
10.4. Distribution channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
10.4.1. Hospital Pharmacies |
10.4.2. Retail Pharmacies |
10.4.3. Others |
10.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
10.5.1. USA |
10.5.2. Canada |
10.6. North America Generic Pharmaceutical Market - Opportunity Analysis Index, By Brand, By Route of Drug Administration, By Application, By Distribution channel, and Country, 2024 - 2030 |
10.7. North America Generic Pharmaceutical Market Dynamics Trends |
11. Europe Generic Pharmaceutical Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
11.1. Brand Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
11.1.1. Pure Generic Drugs |
11.1.2. Branded Generic Drugs |
11.2. Route of Drug Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
11.2.1. Oral |
11.2.2. Topical |
11.2.3. Parental |
11.2.4. Others |
11.3. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
11.3.1. Central Nervous System (CNS) |
11.3.2. Cardiovascular Disease (CVDs) |
11.3.3. Infectious Disease |
11.3.4. Musculoskeletal Disease |
11.3.5. Dermatology |
11.3.6. Oncology |
11.3.7. Respiratory |
11.3.8. Others |
11.4. Distribution channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
11.4.1. Hospital Pharmacies |
11.4.2. Retail Pharmacies |
11.4.3. Others |
11.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
11.5.1. Germany |
11.5.2. UK |
11.5.3. France |
11.5.4. Spain |
11.5.5. Italy |
11.5.6. Rest of Europe |
11.6. Europe Generic Pharmaceutical Market - Opportunity Analysis Index, By Brand, By Route of Drug Administration, By Application, By Distribution channel, and Country, 2024 - 2030 |
11.7. Europe Generic Pharmaceutical Market Dynamics Trends |
12. Asia-Pacific Generic Pharmaceutical Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
12.1. Brand Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
12.1.1. Pure Generic Drugs |
12.1.2. Branded Generic Drugs |
12.2. Route of Drug Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
12.2.1. Oral |
12.2.2. Topical |
12.2.3. Parental |
12.2.4. Others |
12.3. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
12.3.1. Central Nervous System (CNS) |
12.3.2. Cardiovascular Disease (CVDs) |
12.3.3. Infectious Disease |
12.3.4. Musculoskeletal Disease |
12.3.5. Dermatology |
12.3.6. Oncology |
12.3.7. Respiratory |
12.3.8. Others |
12.4. Distribution channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
12.4.1. Hospital Pharmacies |
12.4.2. Retail Pharmacies |
12.4.3. Others |
12.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
12.5.1. China |
12.5.2. India |
12.5.3. Japan |
12.5.4. ASEAN |
12.5.5. Australia & New Zealand |
12.5.6. Rest of Asia-Pacific |
12.6. Asia-Pacific Generic Pharmaceutical Market - Opportunity Analysis Index, By Brand, By Route of Drug Administration, By Application, By Distribution channel, and Country, 2024 - 2030 |
12.7. Asia-Pacific Generic Pharmaceutical Market Dynamics Trends |
13. Latin America Generic Pharmaceutical Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
13.1. Brand Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
13.1.1. Pure Generic Drugs |
13.1.2. Branded Generic Drugs |
13.2. Route of Drug Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
13.2.1. Oral |
13.2.2. Topical |
13.2.3. Parental |
13.2.4. Others |
13.3. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
13.3.1. Central Nervous System (CNS) |
13.3.2. Cardiovascular Disease (CVDs) |
13.3.3. Infectious Disease |
13.3.4. Musculoskeletal Disease |
13.3.5. Dermatology |
13.3.6. Oncology |
13.3.7. Respiratory |
13.3.8. Others |
13.4. Distribution channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
13.4.1. Hospital Pharmacies |
13.4.2. Retail Pharmacies |
13.4.3. Others |
13.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
13.5.1. Brazil |
13.5.2. Mexico |
13.5.3. Rest of Latin America |
13.6. Latin America Generic Pharmaceutical Market - Opportunity Analysis Index, By Brand, By Route of Drug Administration, By Application, By Distribution channel, and Country, 2024 - 2030 |
13.7. Latin America Generic Pharmaceutical Market Dynamics Trends |
14. Middle East and Africa Generic Pharmaceutical Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
14.1. Brand Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
14.1.1. Pure Generic Drugs |
14.1.2. Branded Generic Drugs |
14.2. Route of Drug Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
14.2.1. Oral |
14.2.2. Topical |
14.2.3. Parental |
14.2.4. Others |
14.3. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
14.3.1. Central Nervous System (CNS) |
14.3.2. Cardiovascular Disease (CVDs) |
14.3.3. Infectious Disease |
14.3.4. Musculoskeletal Disease |
14.3.5. Dermatology |
14.3.6. Oncology |
14.3.7. Respiratory |
14.3.8. Others |
14.4. Distribution channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
14.4.1. Hospital Pharmacies |
14.4.2. Retail Pharmacies |
14.4.3. Others |
14.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
14.5.1. Gulf Cooperation Council (GCC) Countries |
14.5.2. South Africa |
14.5.3. Rest of MEA |
14.6. MEA Generic Pharmaceutical Market - Opportunity Analysis Index, By Brand, By Route of Drug Administration, By Application, By Distribution channel, and Country, 2024 - 2030 |
14.7. MEA Generic Pharmaceutical Market Dynamics Trends |
15. Competition Landscape |
15.1. Strategic Dashboard of Top Market Players |
15.2. Company Profiles (Introduction, Financial Analysis, Key Brands, Key Developments, Strategies, and SWOT Analysis) |
15.2.1. Abbott Laboratories |
15.2.2. Amgen |
15.2.3. Apotex |
15.2.4. Mylan |
15.2.5. Pfizer |
15.2.6. ASKA Pharmaceutical |
15.2.7. AstraZeneca |
15.2.8. Baxter International |
15.2.9. Dr. Reddy’s Laboratories |
15.2.10. Eli Lilly and Company |
15.2.11. Endo International |
15.2.12. GlaxoSmithKline |
15.2.13. H. Lundbeck A/S |
15.2.14. Hospira |
15.2.15. Lupin Pharmaceuticals |
15.2.16. Novartis International |
15.2.17. Sanofi-Aventis |
15.2.18. Sun Pharma |
15.2.19. Teva Pharmaceutical Industries Ltd. |
16. Research Methodology |
17. Key Assumptions and Acronyms |
Key Market Players